Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats

Journal of Nephrology

Volumn 24, Issue 1, 2011, Pages 106-111

  Stangou, Maria ^a   Bhangal, Gurjeet ^a   Lai, Ping Chin ^a,b   Smith, Jennifer ^a   Keith Jr , James C ^c   Boyle, Joseph J ^d   Pusey, Charles D ^a   Cook, Terence ^a,d   Tam, Frederick W K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c PFIZER INC   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Extracellular matrix; Glomerulonephritis; IL 11; Myofibroblasts; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; RECOMBINANT INTERLEUKIN 11; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EXTRACELLULAR MATRIX; GLOMERULUS; IMMUNE COMPLEX NEPHRITIS; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT; UPREGULATION;

ACTINS; ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; GLOMERULONEPHRITIS; HUMANS; INTERLEUKIN-11; KIDNEY GLOMERULUS; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, INBRED WKY; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78651060910     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.5094     Document Type: Article

References (24)

1. Trepicchio WL, Dorner AJ. Interleukin-11: a gp130 cytokine. Ann N Y Acad Sci. 1998;856:12-21.
2. Müller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE. 2003;2003:PE40.
3. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1-20.
4. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 1999;13:1307-1315.
5. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165-4172.
6. Ragni MV, Jankowitz RC, Chapman HL, et al. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia. 2008;14:968-977.
7. Schmitz B, Thiele J, Witte O, Kaufmann R, Wickenhauser C, Fischer R. Influence of cytokines (IL-1 alpha, IL-3, IL-11, GMCSF) on megakaryocyte- fibroblast interactions in normal human bone marrow. Eur J Haematol. 1995;55:24-32.
8. Peterson RL, Wang L, Albert L, Keith JC Jr, Dorner AJ. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest. 1998;78:1503-1512.
9. Tang W, Geba GP, Zheng T, et al. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J Clin Invest. 1996;98:2845-2853.
10. Lai PC, Cook HT, Smith J, Keith JC Jr, Pusey CD, Tam FW. Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats. J Am Soc Nephrol. 2001;12:2310-2320.
11. Lai PC, Smith J, Bhangal G, et al. Interleukin-11 reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis. Nephron Exp Nephrol. 2005;101:146-154.
12. Tam FW, Smith J, Morel D, et al. Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant. 1999;14:1658-1666.
13. Martin MM, Buckenberger JA, Jiang J, et al. TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2007;293:790-799.
14. Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. TGF-β1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci. 2001;114:3905-3914.
15. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Gobe G, Johnson DW. Interleukin-1beta induces human proximal tubule cell injury, alpha-smooth muscle actin expression and fibronectin production. Kidney Int. 2002;62:31-40.
16. Kondo S, Kagami S, Urushihara M, et al. Transforming growth factor-beta1 stimulates collagen matrix remodeling through increased adhesive and contractive potential by human renal fibroblasts. Biochim Biophys Acta. 2004;1693:91-100.
17. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19:2282-2287.
18. Goumenos D, Tsomi K, Iatrou C, et al. Myofibroblasts and the progression of crescentic glomerulonephritis. Nephrol Dial Transplant. 1998;13:1652-1661.
19. Roberts IS, Burrows C, Shanks JH, Venning M, McWilliam LJ. Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol. 1997;50:123-127.
20. Zhou A, Ueno H, Shimomura M, et al. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int. 2003;64:92-101.
21. Dickinson RJ, Keyse SM. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci. 2006;119:4607-4615.
22. Ding Q, Gladson CL, Wu H, Hayasaka H, Olman MA. Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem. 2008;283:26839-26849.
23. Kapoun AM, Gaspar NJ, Wang Y, et al. Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol. 2006;70:518-531.
24. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2002;61:1684-1695.